Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Keytruda (pembrolizumab)
i
Other names:
MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(633)
News
Twitter
Trials
Company:
Merck (MSD)
Drug class:
PD1 inhibitor
Related drugs:
‹
nivolumab (508)
sintilimab (86)
toripalimab (76)
camrelizumab (69)
tislelizumab (64)
dostarlimab (29)
cemiplimab (27)
AB122 (16)
PDR001 (14)
ABBV-181 (13)
AGEN2034 (8)
serplulimab (6)
pucotenlimab (6)
retifanlimab (5)
PF-06801591 (5)
MGD013 (5)
penpulimab (4)
nivolumab/relatlimab (4)
JNJ-63723283 (4)
cadonilimab (3)
PSB205 (3)
AK112 (3)
geptanolimab (2)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
MASCT-I (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
nivolumab (508)
sintilimab (86)
toripalimab (76)
camrelizumab (69)
tislelizumab (64)
dostarlimab (29)
cemiplimab (27)
AB122 (16)
PDR001 (14)
ABBV-181 (13)
AGEN2034 (8)
serplulimab (6)
pucotenlimab (6)
retifanlimab (5)
PF-06801591 (5)
MGD013 (5)
penpulimab (4)
nivolumab/relatlimab (4)
JNJ-63723283 (4)
cadonilimab (3)
PSB205 (3)
AK112 (3)
geptanolimab (2)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
MASCT-I (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
›
Associations
(633)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 6 days (New C4)
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 6d
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 6 days
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 6 days - (New C4)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
FDA - 1wk
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week
pembrolizumab
Sensitive
:
A1
FDA - 1 week - (New A1)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 1wk
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 1 week
pembrolizumab
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week (New B)
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1wk
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1 week - (New B)
PD-L1 expression
Solid Tumor
PD-L1 expression
Solid Tumor
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation
Prostate Cancer
CHEK2 mutation
Prostate Cancer
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 2 weeks (New C4)
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 2wk
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 2 weeks
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 2 weeks - (New C4)
TMB-H + PD-L1 expression
Lung Cancer
TMB-H + PD-L1 expression
Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 2 weeks (New C4)
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 2wk
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 2 weeks
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 2 weeks - (New C4)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
ASCO.org - 4 weeks (New A2)
pembrolizumab
Sensitive
:
A2
ASCO.org - 4wk
pembrolizumab
Sensitive: A2 - Guideline
ASCO.org - 4 weeks
pembrolizumab
Sensitive
:
A2
ASCO.org - 4 weeks - (New A2)
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A1 - Approval
pembrolizumab + axitinib
Sensitive
:
A1
pembrolizumab + axitinib
Sensitive: A1 - Approval
pembrolizumab + axitinib
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
No biomarker
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
TMB-H
Solid Tumor
TMB-H
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login